latest update:
[TrialBase DB]

trial summary · NCT07646821

A Phase 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in MDS/AML With TP53 Mutations

Trial record from the TrialBase DB dataset, status RECRUITING, condition Ropeginterferon, sponsored by M.D. Anderson Cancer Center. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07646821phase PHASE1/PHASE2enrollment 30start 2026-10-27

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

To find the recommended dose of ropeginterferon alfa-2b in combination with azacitidine in patients with newly diagnosed MDS/AML with TP53 mutations. To learn if the recommended dose of ropeinterferon alfa-2b found in Dose Escalation in combination with azacitidine can help to control the disease.

Source record: https://clinicaltrials.gov/study/NCT07646821

Facts

registry idNCT07646821
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE1/PHASE2
study typeINTERVENTIONAL
lead conditionRopeginterferon
sponsorM.D. Anderson Cancer Center
sponsor classOTHER
enrollment30
start date2026-10-27
primary completion2028-12-11
completion2030-12-11
results postednot reported

Conditions

  • Ropeginterferon
  • Alfa-2b
  • Azacitidine
  • MDS/AML

Interventions

  • ropeginterferon alfa- 2b
  • Azacitidine (AZA)

Countries

  • United States

Intervention types: DRUG

Work with this record